Episodes

  • Melinda Knows Best at AAD 2026: When the Treatment Algorithm for Chronic Hand Eczema Gets a Plot Twist

    Melinda Knows Best at AAD 2026: When the Treatment Algorithm for Chronic Hand Eczema Gets a Plot Twist
    Apr 16 2026

    🎙️✨ Melinda Knows Best at AAD Denver: Hands Down, Chronic Hand Eczema Is Getting a New Playbook 🖐️

    Live from AAD 2026 in Denver 🏔️, a podcast favorite, Melinda Knows Best returns with Dr. Melinda Gooderham for a true post-game analysis🏀 of new chronic hand eczema data — and yes, this one is all about helping hands get back to doing what hands do best: opening jars 🥜, buttoning shirts 👔, holding coffee cups ☕, and generally not letting everyday life feel just like a clinical endpoint.

    In this episode, we break down new pooled post-hoc data evaluating delgocitinib cream versus vehicle in adults with moderate-to-severe chronic hand eczema, with a practical twist: does prior systemic therapy exposure matter for patient success, especially when it comes to pain and itch? 🤔

    We dive into:

    • Does this data push delgocitinib earlier in the treatment algorithm for Melinda?
    • What are the biggest critiques or caveats a dermatologist should keep in mind when looking at this data?
    • Who is the real-world patient you would think about tomorrow after seeing this poster

    Well the chronic hand eczema treatment ladder may not be a one-way escalator anymore. 🪜🔄

    Dr. Gooderham brings the real-world lens 👩‍⚕️: patients do not just want almost clear skin on a study scale — they want to work, cook, dress, sleep, and live without painful, itchy, fissured hands getting in the way.

    Because when it comes to chronic hand eczema, sometimes the most meaningful outcome is being able to open the peanut butter jar without negotiating with your skin first. 🥜😅

    Learning objectives 📚
    By the end of this episode, listeners will be able to:

    1. Summarize new AAD 2026 data evaluating delgocitinib cream in moderate-to-severe chronic hand eczema based on prior systemic therapy exposure.
    2. Compare response patterns in systemic-naïve versus systemic-experienced patients.
    3. Discuss the real-world clinical relevance of early itch and pain improvement in chronic hand eczema.
    4. Identify key caveats of the analysis, including its post-hoc design, subgroup size, and 16-week timeframe.
    5. Consider how delgocitinib may fit into evolving treatment algorithms for chronic hand eczema.

    #SkinAndJointsPodcast #MelindaKnowsBest #AAD2026 #ChronicHandEczema #HandEczema #EczemaCare #Dermatology #DermatologyPodcast #Delgocitinib #MedicalEducation #HCPeducation #DermTwitter #AADDenver #SkinScience #TopicalTherapy #RealWorldDermatology #IGA #HESD #itch #pain

    Episode supported by and IME Grant from LEO Pharma

    ABOUT Dr.Melinda Gooderham, MD, FRCPC ( Dermatology)

    Toronto, ON

    Melinda Gooderham MD MSc FRCPC Dr. Gooderham is a Dermatologist and Medical Director at the SKiN Centre for Dermatology and an Investigator with Probity Medical Research. She is an Assistant Professor at Queens University and a Consultant Physician at the Peterborough Regional Health Centre. She is a fellow of the Royal College of Physicians and Surgeons of Canada.

    Dr. Gooderham has been the principal investigator for over 200 clinical trials and she practices with a focus on inflammatory diseases of the skin. She also contributes to several peer-reviewed dermatology publications as an associate editor, reviewer, and has been an author of 205 articles. She enjoys lecturing to global audiences on new therapies for skin diseases.

    📻www.skinandjoints.ca

    ✉️info@skinandjoints.ca

    📻www.skinandjoints.ca

    ✉️info@skinandjoints.ca


    Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
    Show More Show Less
    21 mins
  • When Isotretinoin Isn’t Flying Solo: The Case for Combo Topical Acne Care at AAD 2026 with Dr. Renée A. Beach and Dr. Irina Oroz

    When Isotretinoin Isn’t Flying Solo: The Case for Combo Topical Acne Care at AAD 2026 with Dr. Renée A. Beach and Dr. Irina Oroz
    Apr 15 2026

    🎙️✨ Isotretinoin + Clascoterone: Acne’s New Power Couple?

    When acne gets severe, isotretinoin usually enters the chat as the big gun.💥
    But what happens when you pair it with topical clascoterone — the anti-androgen sidekick targeting the sebaceous gland from another angle?

    In this episode, we break down new real-world data from a multi-centre retrospective study comparing oral isotretinoin monotherapy versus combination isotretinoin + topical clascoterone for severe acne vulgaris and what the implications are for clinic.

    And yes — the combo arm brought some serious main-character energy.

    Our expert guests unpack what this could mean in clinic:
    ✨ faster clearance
    ✨ improved tolerability
    ✨ hormonal acne considerations
    ✨ patient adherence realities
    ✨ the ever-important goal of preventing scars before they happen

    Because in acne care, almost clear is nice… but clear-clear is the assignment. ✅

    This conversation dives into the practical side: When should clascoterone be added? Which patients may benefit most? How do we keep regimens simple for younger patients already juggling isotretinoin, labs, moisturizers, sunscreen, and TikTok skincare detox?

    Learning objectives:
    ✅ Review emerging data comparing isotretinoin monotherapy with isotretinoin plus topical clascoterone in severe acne vulgaris
    ✅ Discuss the potential clinical relevance of combination therapy for clearance, tolerability, and patient experience
    ✅ Explore practical approaches to integrating clascoterone into isotretinoin treatment plans
    ✅ Consider real-world limitations of retrospective data, including confounders, dosing variation, skincare use, and patient selection
    ✅ Reframe acne treatment goals beyond lesion counts to include scarring prevention, satisfaction, and long-term disease control

    🎧 AAD 2026 coverage from the Mile High City. Special thanks Dr. Mohannad Abu-Hilal.

    #SkinAndJointsPodcast #AAD2026 #Dermatology #Acne #AcneVulgaris #Isotretinoin #Clascoterone #Winlevi #DermTwitter #MedEd #DermatologyEducation #SevereAcne #AcneScarring #SkinHealth #ClinicalDermatology #Vodcast #Podcast #HealthcareEducation

    ABOUT Dr. Renée A. Beach MD FRCPC DABD Dermatologist | Toronto, ON

    Dr. Renée A. Beach is a dermatologist practicing in Toronto for more than 10 years. She earned her medical doctor (MD) degree from McMaster University, followed by Dermatology residency at the University of Ottawa (FRCPC).

    As an adjunct assistant professor at the University of Toronto, she teaches trainees in the Undergraduate MD program as well as postgraduate dermatology residents and has collaborated with them on various peer-reviewed publications. She is a trusted, regularly sought-after authority across media outlets and is the on-air dermatologist for CTVs The Social and Your Morning. On social media, she is active on Instagram (@dermabeach).

    At her private office, DermAtelier on Avenue, she sees patients for medical and cosmetic treatments with the goal of delivering dermatologic excellence to patients of all skin tones and types

    About Dr. Irina Oroz, MD FRCPC DABD Dermatologist | Saskatoon, SK

    Dr. Irina Oroz is a fellow of the Royal College of Physicians and Surgeons of Canada in Dermatology, a Diplomate of the American Board of Dermatology, and Assistant Clinical Professor of Dermatology at the University of Saskatchewan.

    Currently she practices medical, surgical and cosmetic dermatology at Oroz Dermatology in Saskatoon. Her areas of interest lie in skin cancer, acne and psoriasis.

    Dr. Oroz completed her medical degree at the University of Saskatchewan, prior to undertaking a five-year dermatology residency program at the University of Saskatchewan and University of Alberta. Her interest in the diagnosis and management of skin disease has been enhanced with elective training in USA, Australia and across Canada, with specialized training in Skin Cancer at the Royal Alexandra Hospital in Brisbane Australia, as well as medical education research in Edmonton.

    Active in the medical community, Dr. Oroz is one of the founding members, as well as the current treasurer of the Saskatchewan Dermatology Association.

    Supported by an IME Grant from SUN Pharma.

    📻www.skinandjoints.ca

    ✉️info@skinandjoints.ca


    Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
    Show More Show Less
    21 mins
  • Sebum Like It Hot: New 52-Week Acne Data from AAD 2026 with Dr. Renée A. Beach and Dr. Irina Oroz

    Sebum Like It Hot: New 52-Week Acne Data from AAD 2026 with Dr. Renée A. Beach and Dr. Irina Oroz
    Apr 13 2026

    🎙️✨ New Acne Data Just Dropped — and We’re Bringing the Post-Game Analysis from AAD 2026! 🏀

    Live from Denver — the Mile High City — the Skin and Joints Podcast is breaking down new 52-week real-world acne data exploring the impact of clascoterone 1% on sebum reduction, acne improvement, tolerability, and what it actually means in day-to-day dermatology practice.

    Because let’s be honest: in acne care, it’s not just about lesion counts. Patients care about oiliness, shine, pores, irritation, post-inflammatory marks, and whether their treatment routine feels like a science experiment before bed.

    In this episode, Dr. Renée A. Beach and Dr. Irina Oroz (and a mystery guest co-host ;)) join the conversation to unpack the clinical relevance of the data — and why “treat-to-happy” might just be the endpoint patients really care about.

    We also get into the practical side:
    ✅How do you layer clascoterone with retinoids?
    ✅What does sebum reduction actually mean in clinic?
    ✅Is “zero irritation” too good to be true — or reflective of real-world experience?
    ✅And most importantly… is it pronounced sebometer or sebumeter?

    From male acne patients who now have a topical anti-androgen option, to patients who have tried everything, to those who need a tolerable long-term acne strategy — this episode explores where the data meets the real world.

    Learning Objectives:
    ✅ Review new 52-week data on clascoterone 1% and sebum reduction in acne
    ✅ Discuss the clinical relevance of sebum, shine, oiliness, and patient-reported treatment success
    ✅ Evaluate long-term acne outcomes including IGA success, inflammatory and non-inflammatory lesion reduction, and tolerability
    ✅ Explore practical strategies for layering clascoterone with retinoids, benzoyl peroxide, and combo topical therapies
    ✅ Identify patient profiles who may benefit from topical anti-androgen therapy in real-world practice

    ABOUT Dr. Renée A. Beach MD FRCPC DABD Dermatologist | Toronto, ON

    Dr. Renée A. Beach is a dermatologist practicing in Toronto for more than 10 years. She earned her medical doctor (MD) degree from McMaster University, followed by Dermatology residency at the University of Ottawa (FRCPC).

    As an adjunct assistant professor at the University of Toronto, she teaches trainees in the Undergraduate MD program as well as postgraduate dermatology residents and has collaborated with them on various peer-reviewed publications. She is a trusted, regularly sought-after authority across media outlets and is the on-air dermatologist for CTVs The Social and Your Morning. On social media, she is active on Instagram (@dermabeach).

    At her private office, DermAtelier on Avenue, she sees patients for medical and cosmetic treatments with the goal of delivering dermatologic excellence to patients of all skin tones and types

    About Dr. Irina Oroz, MD FRCPC DABD Dermatologist | Saskatoon, SK

    Dr. Irina Oroz is a fellow of the Royal College of Physicians and Surgeons of Canada in Dermatology, a Diplomate of the American Board of Dermatology, and Assistant Clinical Professor of Dermatology at the University of Saskatchewan.

    Currently she practices medical, surgical and cosmetic dermatology at Oroz Dermatology in Saskatoon. Her areas of interest lie in skin cancer, acne and psoriasis.

    Dr. Oroz completed her medical degree at the University of Saskatchewan, prior to undertaking a five-year dermatology residency program at the University of Saskatchewan and University of Alberta. Her interest in the diagnosis and management of skin disease has been enhanced with elective training in USA, Australia and across Canada, with specialized training in Skin Cancer at the Royal Alexandra Hospital in Brisbane Australia, as well as medical education research in Edmonton.

    Active in the medical community, Dr. Oroz is one of the founding members, as well as the current treasurer of the Saskatchewan Dermatology Association.

    Supported by an IME Grant from SUN Pharma.


    📻www.skinandjoints.ca

    ✉️info@skinandjoints.ca


    Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
    Show More Show Less
    35 mins
  • Age, Risk, and the JAK Factor: A 6-Year Safety Deep Dive from AAD 2026

    Age, Risk, and the JAK Factor: A 6-Year Safety Deep Dive from AAD 2026
    Apr 9 2026
    🎙️ Age, Risk, and the JAK Factor: A 6-Year Safety Deep Dive- Part 2 Guests: Dr. Marissa Joseph and Dr. Fiona LovegroveLocation: 📍 AAD 2026 We’re back with Part 2 of our atopic dermatitis double-header with Dr. Marissa Joseph and Dr. Fiona Lovegrove from AAD 2026 in Denver—and this time, we’re getting into the data that always enters the chat when JAK inhibitors in Atopic Dermatitis are mentioned: long-term safety. Our expert faculty unpack fresh 6-year safety data on upadacitinib in moderate-to-severe atopic dermatitis—looking beyond efficacy and into the real-world clinical questions dermatologists face every day: 🧩 Who is the right patient?⚖️ How do we balance real world risk vs benefit?👵 Does anything change when a patient is over 65? Or is it about how risk is really framed?💉 Where does zoster vaccination fit into the treatment conversation? 📊 And how do we contextualize MACE, VTE, malignancy, infections, and herpes zoster without turning nuance into noise? Because let’s be honest: when it comes to JAK inhibitors, the safety conversation doesn’t just knock politely—it pulls up a chair. 🪑 This episode dives into how long-term data can help clinicians move beyond blanket “yes/no” thinking and toward more individualized decision-making: age, comorbidity stacking, dose, baseline risk, quality of life, disease severity, and patient preference all matter. The big takeaway? Decisions in the gray zone—and that’s exactly where expert interpretation matters most. 🎯 Learning Objectives: By the end of this episode, listeners will be able to: Discuss the clinical relevance of long-term safety data for upadacitinib in moderate-to-severe atopic dermatitis.Identify key safety considerations, including herpes zoster, serious infections, MACE, VTE, and malignancy.Describe how age, comorbidities, dose selection, and baseline patient risk influence treatment decisions with oral JAK inhibitors.Explain the role of shared decision-making and risk-benefit communication when treating adolescents, adults, and older patients with AD.Recognize practical considerations around zoster vaccination and routine immunization when initiating JAK inhibitor therapy. 🎧 Tune in for a practical, nuanced, and slightly puppy-interrupted breakdown of what this data actually means for your clinic. #SkinAndJointsPodcast #AAD2026 #AtopicDermatitis #Dermatology #JAKInhibitors #Upadacitinib #Rinvoq #EczemaCare #DermTwitter #MedEd #HCPeducation #DermatologyPodcast #Vodcast #ClinicalPearls #SharedDecisionMaking #SkinScience #ADTreatment REFERENCE: Long-Term 6-Year Safety of Upadacitinib in Moderate-to-Severe Atopic Dermatitis Across Ages: Results From Three Phase 3 Studies ABOUT Dr. Marissa Joseph MD FRCPC TORONTO, ON DERMATOLOGIST AND PEDIATRICIAN Dr. Marissa Joseph is an Associate Professor at the University of Toronto and the Medical Director of the Ricky Kanee Schachter Dermatology Centre at Women’s College Hospital. She also practices at The Hospital for Sick Children (SickKids), where she cares for children with complex skin disease in both clinic and inpatient settings and leads a pediatric laser program. Her clinical work spans general adult, pediatric, and surgical dermatology. Internationally recognized for her expertise in pediatric dermatology, inflammatory skin disorders, and equity, diversity, and inclusion in dermatologic care, Dr. Joseph has authored book chapters and numerous peer-reviewed publications. She has also been honoured for excellence in teaching at the University of Toronto. Her vision for the field is both simple and ambitious: equitable, high-quality dermatologic care for everyone. ABOUT Dr. Fiona Lovegrove MD FRCPC LONDON, ON DERMATOLOGIST Dr. Fiona Lovegrove is a board-certified dermatologist and founder of Lovegrove Dermatology in London, Ontario. She earned her MD and PhD at the University of Toronto, where she also completed her dermatology residency. A Fellow of the Royal College of Physicians and Surgeons of Canada, she holds an academic appointment as Adjunct Professor at the Schulich School of Medicine & Dentistry.Her clinical expertise includes psoriasis, eczema, skin cancer, and complex diseases such as bullous pemphigoid. Actively engaged in research and clinical trials, she has contributed to publications, conferences, national and global advisory boards and is a GRAPPA member. Dr. Lovegrove is committed to providing patient-centered, evidence-based dermatology care. Supported by an IME Grant from ABBVIE.. 📻www.skinandjoints.ca✉️info@skinandjoints.ca Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
    Show More Show Less
    28 mins
  • AAD 2026: If They Get There, Do They Stay There? A 140-Week AD JAK Data Dive

    AAD 2026: If They Get There, Do They Stay There? A 140-Week AD JAK Data Dive
    Apr 7 2026
    🎙️ If They Get There, Do They Stay There? A 140-Week AD Data Dive — Part 1 of a 2-Part Double Header Guests: Dr. Marissa Joseph and Dr. Fiona LovegroveLocation: 📍 AAD 2026 We came to Denver for AAD 2026, adjusted to the altitude, caught our breath — barely — and dove straight into the data. In Part 1 of this two-part atopic dermatitis double header, Dr. Marissa Joseph and Dr. Fiona Lovegrove join us live from the Mile High City to break down fresh new clinical data in moderate-to-severe atopic dermatitis, with a focus on long-term maintenance of stringent patient-reported outcomes with upadacitinib from the Measure Up 1 and Measure Up 2 studies. Because patients do not walk into clinic asking if their EASI score improved by 70%. They ask: “Will I sleep?”“Will the itch stop?”“Can I focus at work or school?”“Can I stop thinking about my eczema every single day?” Our conversation gets into the so what behind the numbers —what this data implies for your real world patient decisions, why durability matters, why week 16 response may help guide long-term expectations, and why patient-reported outcomes are moving from nice-to-have to true treatment targets in atopic dermatitis. We also explore the challenge of measuring multiple domains in practice, and why aiming high does not mean treating partial responders as failures. How do our experts frame better sleep, less itch, and fewer daily disease interruptions for these partial responders? Think of this as your compact AAD post-game analysis — but instead of Shaq and the scoreboard, we’re breaking down itch, sleep, emotional burden, dose optimization, and the future of treat-to-target AD care. Learning Objectives: By the end of this episode, listeners will be able to: Describe the clinical relevance of long-term patient-reported outcome data in moderate-to-severe atopic dermatitis.Discuss how itch, sleep, emotional burden, and daily functioning can inform treatment success beyond skin clearance alone.Interpret the significance of sustained responses from week 16 through longer-term follow-up in the Measure Up 1 and 2 studies.Identify practical considerations and limitations when incorporating stringent PRO targets into real-world dermatology practice.Apply key insights from AAD 2026 data to therapeutic decision making, patient counselling, expectation-setting, and shared decision-making in AD care. Skin and Joints Podcast — where we bring the science, the clinical translation, and just enough altitude-related commentary to keep things interesting. Part 2 is already warming up in the bullpen. REFERENCES: Long-Term Maintenance of Stringent Patient-Reported Outcomes With Upadacitinib in Moderate-to-Severe Atopic Dermatitis: 140-Week Results From the Measure Up 1 and 2 Phase 3 Studies #SkinAndJointsPodcast #AAD2026 #AtopicDermatitis #EczemaCare #Dermatology #PatientReportedOutcomes #JAKInhibitors #Upadacitinib #MeasureUp #DermatologyEducation #MedicalEducation #HCPeducation #TreatToTarget #InflammatorySkinDisease #ClinicalData #DermTwitter #MedEd #Vodcast #PodcastEpisode #AADDenver #JAK #JAKinhibitor ABOUT Dr. Marissa Joseph MD FRCPC TORONTO, ON DERMATOLOGIST AND PEDIATRICIAN Dr. Marissa Joseph is an Associate Professor at the University of Toronto and the Medical Director of the Ricky Kanee Schachter Dermatology Centre at Women’s College Hospital. She also practices at The Hospital for Sick Children (SickKids), where she cares for children with complex skin disease in both clinic and inpatient settings and leads a pediatric laser program. Her clinical work spans general adult, pediatric, and surgical dermatology. Internationally recognized for her expertise in pediatric dermatology, inflammatory skin disorders, and equity, diversity, and inclusion in dermatologic care, Dr. Joseph has authored book chapters and numerous peer-reviewed publications. She has also been honoured for excellence in teaching at the University of Toronto. Her vision for the field is both simple and ambitious: equitable, high-quality dermatologic care for everyone. ABOUT Dr. Fiona Lovegrove MD FRCPC LONDON, ON DERMATOLOGIST Dr. Fiona Lovegrove is a board-certified dermatologist and founder of Lovegrove Dermatology in London, Ontario. She earned her MD and PhD at the University of Toronto, where she also completed her dermatology residency. A Fellow of the Royal College of Physicians and Surgeons of Canada, she holds an academic appointment as Adjunct Professor at the Schulich School of Medicine & Dentistry.Her clinical expertise includes psoriasis, eczema, skin cancer, and complex diseases such as bullous pemphigoid. Actively engaged in research and clinical trials, she has contributed to publications, conferences, national and global advisory boards and is a GRAPPA member. Dr. Lovegrove is committed to providing patient-centered, evidence-based dermatology care. Supported by an IME Grant from ABBVIE.. 📻...
    Show More Show Less
    26 mins
  • World Psoriasis Day: From Stigma to Skin Clearance with Dr. Jessica Asgarpour

    World Psoriasis Day: From Stigma to Skin Clearance with Dr. Jessica Asgarpour
    Oct 28 2025

    🎙️ World Psoriasis Day Special

    This special World Psoriasis Day episode of The Skin and Joints Podcast shines a light on the evolving psoriasis journey—from the first plaque to total skin clearance. Dermatologist Dr. Jessica Asgarpour, now back in her sunny hometown of Calgary, joins us for an honest, hopeful conversation about how far psoriasis care has come—and where it’s headed next.

    From coal tar and cumbersome creams to once-every-12-week biologic injections, Dr. Asgarpour unpacks the “treatment ladder” and what really determines when to climb it. Together they explore:

    Why World Psoriasis Day (Oct 29) matters for awareness, stigma reduction, and timely re-referral

    How to recognize when a patient is undertreated and ready for escalation

    The topical-to-systemic continuum—including steroid-free innovations, orals vs. biologics, and the occasional role for IV therapy

    Real-world barriers in access and adherence—from referral deserts to needle phobia

    Matching therapy to patient lifestyle, comorbidities, and comfort level (“the clinic playbook”)

    Why dermatologists today can say, confidently, that there is hope for every patient

    It’s part myth-busting, part motivation—a must-listen whether you’re a clinician optimizing care or a patient ready to revisit your treatment options.

    🎯 Learning Objectives

    After listening to this episode, participants will be able to:

    • Describe the modern therapeutic ladder for psoriasis, from topicals and orals to biologics and infusions.
    • Identify clinical and quality-of-life criteria that signal the need for treatment escalation.
    • Discuss common barriers leading to undertreatment and strategies to enhance patient access and adherence.
    • Compare classes of biologic agents (TNF-α, IL-17, IL-23, IL-12/23) and their practical considerations in real-world care.
    • Empower patients with evidence-based reassurance about safety, efficacy, and long-term outcomes of advanced therapies.

    🩵 World Psoriasis Day is more than awareness—it’s a call to action for clear skin, renewed confidence, and collaborative care.
    #WorldPsoriasisDay #SkinAndJointsPodcast #PsoriasisAwareness #Dermatology #Biologics #PatientJourney #ClearSkinAhead

    Supported by SUN Pharma.

    ABOUT Dr. Jessica Asgarpour Dermatologist, Calgary, AB

    Board-certified in both Canada and the U.S., Dr. Asgarpour completed medical school at the Cumming School of Medicine and her Dermatology residency at the University of Alberta. She practices medical, surgical, and cosmetic dermatology with a special interest in hidradenitis suppurativa and deroofing surgeries, as well as acne, psoriasis, eczema, skin cancer, and women’s health. She is currently working at the Skin Health and Wellness Centre in Calgary. She is a lecturer at the University of Toronto, a courtesy clinical associate at Women’s College Hospital, and is an active investigator for ongoing clinical trials in inflammatory diseases. She is a board member on the Canadian Hidradenitis Suppurativa foundation.

    📻www.skinandjoints.ca

    ✉️info@skinandjoints.ca

    📻www.skinandjoints.ca

    ✉️info@skinandjoints.ca


    Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
    Show More Show Less
    30 mins
  • (PART 2) Acne in Paris: Croissants, Comedones & Cutting-Edge Care at EADV 2025

    (PART 2) Acne in Paris: Croissants, Comedones & Cutting-Edge Care at EADV 2025
    Oct 8 2025
    Acne in Paris: Croissants, Comedones & Cutting-Edge Care at EADV 2025Guests: Dr. Chloe Ward & Dr. Natalie CunninghamLocation: 📍 EADV 2025, Paris 🇫🇷From café chatter to late-breaker abstracts, this fresh field report stitches together breaking new data and what matters for acne care today. Our two Canadian derm Faculty dynamos, Dr. Chloe Ward and Dr. Natalie Cunningham, join us live from EADV 2025 to decode acne in the TikTok age. We swap “Dr. Google” for real talk on psychosocial fallout (filters, FOMO, and 4 a.m. routines), sanity-check the diet myths, and map where AI actually helps in assessment—think consistent severity tracking and smarter primary-care triage—without replacing clinical eyes (especially in richer skin tones).Drs. Ward and Cunningham unpack multimodal regimens patients can actually tolerate, topical androgen-receptor blockade at the sebaceous unit, and smarter maintenance so scars don’t steal the show. We dig into pigment beyond classic PIH (hello, primary melanogenesis), when energy devices earn a seat (including a 1726-nm sebaceous-targeting laser), why most at-home red light is a detour, and the rare moments biologics enter the chat for overlap/refractory cases. Throughout: practical pearls and fresh evidence Learning ObjectivesAfter this episode, participants will be able to:🧠 Assess psychosocial burden in acne (sleep 💤, stress 😰, social media behaviors 📱) and integrate into severity and treatment decisions 🩺.🥗 Debunk prevalent myths (“diet cures acne” ❌) with balanced, evidence-based counseling 📖 that acknowledges diet/stress/hormones as contributors, not sole causes ⚖️.🧴 Design patient-centered, multimodal regimens that optimize efficacy ✅ and tolerability 🤝—leveraging combination therapy 🔗.🧬 Explain mechanisms (incl. topical androgen-receptor blockade at the sebaceous gland) and position them in stepwise care from induction 🚀 to maintenance 🔁.🎨 Differentiate pigment pathways (PIH vs. emerging primary melanogenesis) and tailor strategies for all skin tones 🌈 with rigorous photoprotection 🧢🕶️.🤖 Use AI judiciously for documentation 📝 and triage 🏥; recognize limitations in diverse skin tones 🌍 and keep the patient’s lived experience central ❤️.🛡️ Prevent scars proactively by identifying scar-risk patients early ⏱️ and escalating appropriately (e.g., isotretinoin candidacy) 🎯.🔦 Outline the role of energy-based devices (including the 1726-nm sebaceous-targeting laser) in reducing inflammation 🔥, erythema 🌺, and remodeling 🧱—and why most at-home red-light devices fall short 🚫🔴.🧬 Spot the edge cases where biologics or overlap-syndrome thinking may be appropriate 🧩, and outline key research gaps to watch 🔭 (hormonal pathways, AI validation, long-term maintenance). Perfect forDermatologists, primary-care clinicians, pharmacists, nurses, and any HCP who fields “I saw this on TikTok…” and wants practical, patient-first to translate Paris-level science into Monday-morning care. ABOUT Dr Natalie Cunningham, MD FRCPC HALIFAX, NSDr. Cunningham is a co-founder of Maritime Dermatology and was born and raised in Halifax, Nova Scotia. Her roots are in Yarmouth, Nova Scotia and Vienna, Austria. She completed a Bachelor of Science in Neuroscience, Medical School and Dermatology Residency, serving as chief resident, at Dalhousie University. She passed her Royal College examination in 2017. She has been active in medical education and is assistant professor in the department of medicine at Dalhousie medical school. She sees patients of all ages and has a pediatric dermatology clinic at the IWK where she also supervises medical students and residents. She is active in research and has publications in high impact scientific journals and is the research director at Maritime Dermatology. ABOUT Dr. Chloé Ward, MD, FRCP(C), DABD OTTAWA, ONChloé Ward, MD, FRCP(C), DABD is a board-certified dermatologist working alongside our team of plastic surgeons at The Ottawa Clinic. She specializes in cutaneous laser surgery and helps patients with a wide range of cosmetic and medical skin care needs. ABOUT Dr Natalie Cunningham, MD FRCPC HALIFAX, NSDr. Cunningham is a co-founder of Maritime Dermatology and was born and raised in Halifax, Nova Scotia. Her roots are in Yarmouth, Nova Scotia and Vienna, Austria. She completed a Bachelor of Science in Neuroscience, Medical School and Dermatology Residency, serving as chief resident, at Dalhousie University. She passed her Royal College examination in 2017. She has been active in medical education and is assistant professor in the department of medicine at Dalhousie medical school. She sees patients of all ages and has a pediatric dermatology clinic at the IWK where she also supervises medical students and residents. She is active in research and has publications in high impact ...
    Show More Show Less
    23 mins
  • Acne in Paris: Croissants, Comedones & Cutting-Edge Care at EADV 2025

    Acne in Paris: Croissants, Comedones & Cutting-Edge Care at EADV 2025
    Oct 6 2025
    Acne in Paris: Croissants, Comedones & Cutting-Edge Care at EADV 2025Guests: Dr. Chloe Ward & Dr. Natalie CunninghamLocation: 📍 EADV 2025, Paris 🇫🇷From café chatter to late-breaker abstracts, this fresh field report stitches together breaking new data and what matters for acne care today. Our two Canadian derm Faculty dynamos, Dr. Chloe Ward and Dr. Natalie Cunningham, join us live from EADV 2025 to decode acne in the TikTok age. We swap “Dr. Google” for real talk on psychosocial fallout (filters, FOMO, and 4 a.m. routines), sanity-check the diet myths, and map where AI actually helps in assessment—think consistent severity tracking and smarter primary-care triage—without replacing clinical eyes (especially in richer skin tones).Drs. Ward and Cunningham unpack multimodal regimens patients can actually tolerate, topical androgen-receptor blockade at the sebaceous unit, and smarter maintenance so scars don’t steal the show. We dig into pigment beyond classic PIH (hello, primary melanogenesis), when energy devices earn a seat (including a 1726-nm sebaceous-targeting laser), why most at-home red light is a detour, and the rare moments biologics enter the chat for overlap/refractory cases. Throughout: practical pearls and fresh evidence Learning ObjectivesAfter this episode, participants will be able to:🧠 Assess psychosocial burden in acne (sleep 💤, stress 😰, social media behaviors 📱) and integrate into severity and treatment decisions 🩺.🥗 Debunk prevalent myths (“diet cures acne” ❌) with balanced, evidence-based counseling 📖 that acknowledges diet/stress/hormones as contributors, not sole causes ⚖️.🧴 Design patient-centered, multimodal regimens that optimize efficacy ✅ and tolerability 🤝—leveraging combination therapy 🔗.🧬 Explain mechanisms (incl. topical androgen-receptor blockade at the sebaceous gland) and position them in stepwise care from induction 🚀 to maintenance 🔁.🎨 Differentiate pigment pathways (PIH vs. emerging primary melanogenesis) and tailor strategies for all skin tones 🌈 with rigorous photoprotection 🧢🕶️.🤖 Use AI judiciously for documentation 📝 and triage 🏥; recognize limitations in diverse skin tones 🌍 and keep the patient’s lived experience central ❤️.🛡️ Prevent scars proactively by identifying scar-risk patients early ⏱️ and escalating appropriately (e.g., isotretinoin candidacy) 🎯.🔦 Outline the role of energy-based devices (including the 1726-nm sebaceous-targeting laser) in reducing inflammation 🔥, erythema 🌺, and remodeling 🧱—and why most at-home red-light devices fall short 🚫🔴.🧬 Spot the edge cases where biologics or overlap-syndrome thinking may be appropriate 🧩, and outline key research gaps to watch 🔭 (hormonal pathways, AI validation, long-term maintenance). Perfect forDermatologists, primary-care clinicians, pharmacists, nurses, and any HCP who fields “I saw this on TikTok…” and wants practical, patient-first to translate Paris-level science into Monday-morning care. ABOUT Dr Natalie Cunningham, MD FRCPC HALIFAX, NSDr. Cunningham is a co-founder of Maritime Dermatology and was born and raised in Halifax, Nova Scotia. Her roots are in Yarmouth, Nova Scotia and Vienna, Austria. She completed a Bachelor of Science in Neuroscience, Medical School and Dermatology Residency, serving as chief resident, at Dalhousie University. She passed her Royal College examination in 2017. She has been active in medical education and is assistant professor in the department of medicine at Dalhousie medical school. She sees patients of all ages and has a pediatric dermatology clinic at the IWK where she also supervises medical students and residents. She is active in research and has publications in high impact scientific journals and is the research director at Maritime Dermatology. ABOUT Dr. Chloé Ward, MD, FRCP(C), DABD OTTAWA, ONChloé Ward, MD, FRCP(C), DABD is a board-certified dermatologist working alongside our team of plastic surgeons at The Ottawa Clinic. She specializes in cutaneous laser surgery and helps patients with a wide range of cosmetic and medical skin care needs. ABOUT Dr Natalie Cunningham, MD FRCPC HALIFAX, NSDr. Cunningham is a co-founder of Maritime Dermatology and was born and raised in Halifax, Nova Scotia. Her roots are in Yarmouth, Nova Scotia and Vienna, Austria. She completed a Bachelor of Science in Neuroscience, Medical School and Dermatology Residency, serving as chief resident, at Dalhousie University. She passed her Royal College examination in 2017. She has been active in medical education and is assistant professor in the department of medicine at Dalhousie medical school. She sees patients of all ages and has a pediatric dermatology clinic at the IWK where she also supervises medical students and residents. She is active in research and has publications in high impact ...
    Show More Show Less
    20 mins